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ABSTRACT
Antimicrobial resistance of Shigella isolates in Bangladesh, during 2001-2002, was studied and com-
pared with that of 1991-1992 to identify the changes in resistance patterns and trends. A significant 
increase in resistance to trimethoprim-sulphamethoxazole (from 52% to 72%, p<0.01) and nalidixic 
acid (from 19% to 51%, p<0.01) was detected. High, but unchanged, resistance to tetracycline, am-
picillin, and chloramphenicol, low resistance to mecillinam (resistance 3%, intermediate 3%), and 
to emergence of resistance to azithromycin (resistance 16%, intermediate 62%) and ceftriaxone/ce-
fixime (2%) were detected in 2001-2002. Of 266 recent isolates, 63% were resistant to ≥3 anti-Shigella 
drugs (multidrug-resistant [MDR]) compared to 52% of 369 strains (p<0.007) in 1991-1992. Of 154 
isolates tested by E-test in 2001-2002, 71% were nalidixic acid-resistant (minimum inhibitory con-
centration [MIC] ≥32 µg/mL) and had 10-fold higher MIC90 (0.25 µg/mL) to ciprofloxacin than that 
of nalidixic acid-susceptible strains exhibiting decreased ciprofloxacin susceptibility, which were de-
tected as ciprofloxacin-susceptible and nalidixic acid-resistant by the disc-diffusion method. These 
strains were frequently associated with MDR traits. High modal MICs were observed to azithromy-
cin (MIC 6 µg/mL) and nalidixic acid (MIC 128 µg/mL) and low to ceftriaxone (MIC 0.023 µg/mL). 
Conjugative R-plasmids-encoded extended-spectrum ß-lactamase was responsible for resistance to 
ceftriaxone/cefixime. The growing antimicrobial resistance of Shigella is worrying and mandates 
monitoring of resistance. Pivmecillinam or ciprofloxacin might be considered for treating shigellosis 
with caution.
Key words: Azithromycin; Ciprofloxacin; Drug resistance, Microbial; E-test; Microbial sensitivity 
tests; Nalidixic acid; R-plasmid; Shigella; Bangladesh
Correspondence and reprint requests should be 
addressed to:
Dr. Mahbubur Rahman
Scientist, Laboratory Sciences Division
ICDDR,B 
GPO Box 128, Dhaka 1000
(Mohakhali, Dhaka 1212)
Bangladesh
Email: mahbubur@icddrb.org
Fax: (880-2) 8812529 
INTRODUCTION
Shigellosis is one of the significant causes of diar-
rhoeal diseases in the developing world. World-
wide, an estimated 165 million cases and 1.1 
million deaths (mostly in developing countries) 
occur annually (1-4). Antimicrobial therapy has 
been recommended for patients with shigellosis 
because it can limit the clinical course of ill-
ness and reduce the risk of complications and 
the duration of faecal excretion of the causative 
organism, reducing the spread of infection (2-
5). The therapy also improves the growth and 
nutritional status of affected children, especially 
in developing countries (5). A major problem, 
however, is the increasing resistance of Shigella 
spp. to useful antimicrobial agents (3,6-11). 
Over the decades, Shigella isolates resistant to mul-
tiple agents, such as sulphonamides, tetracycline, 
ampicillin, trimethoprim-sulphamethoxazole 
(SXT), and nalidixic acid have been reported 
from many countries, including Bangladesh (3,6-
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11), resulting in difficulties in the selection of 
empirical therapy. However, newer antimicrobial 
agents, such as mecillinam, ciprofloxacin, ceftri-
axone, cefixime, and azithromycin, were found 
to be effective in treating multidrug-resistant 
Shigella-associated infections (6,12-14). Recently, 
Shigella strains resistant to ciprofloxacin have 
emerged in Bangladesh and India (8,15-16). 
Currently, we do not have sufficient informa-
tion on the susceptibility patterns of Shigella 
isolates to many useful antimicrobial agents, 
such as mecillinam, ciprofloxacin, levofloxacin, 
azithromycin, ceftriaxone, and cefixime. Given 
the impact of suboptimal use of antimicrobial 
agents in Bangladesh and the ability of Shigella 
to develop resistance after the introduction of 
new antimicrobial agents for treatment, it is not 
unlikely that antimicrobial resistance patterns 
in Bangladesh have changed since they were 
reported in the 1990s (11). Thus, the continuing 
changing patterns of resistance of Shigella isolates 
indicate the need for monitoring antimicrobial 
susceptibility. We, therefore, investigated the 
trends in antimicrobial resistance of Shigella isolates 
and compared these with previous data to suggest 
timely recommendations for empirical antimi-
crobial therapy, if needed.
MATERIALS AND METHODS
Clinical samples and bacterial strains
The sources of faecal samples were diarrhoeal 
patients who attended the Dhaka Hospital of 
ICDDR,B and whose clinical conditions required 
stool cultures in a microbiology laboratory as sug-
gested by physicians during the study period. All 
relevant laboratory data were archived. We ana-
lyzed resistance to useful antimicrobial agents of 
369 (8%) of 4,597 Shigella strains isolated in the 
Clinical Laboratory of ICDDR,B, which were col-
lected monthly (32-33 strains per month) during 
1991-1992. To compare data on antimicrobial re-
sistance with those of 1991-1992, we studied 266 
(8%, 22-23 strains monthly) of 3,337 Shigella iso-
lates cultured during 2001-2002.
Microbiological techniques
Faecal samples were cultured onto MacConkey 
and Salmonella-Shigella agars for the isolation of 
Shigella spp., which were identified biochemi-
cally by the standard methods (17) and grouped 
serologically by slide agglutination with specific 
antisera (Denka Saiken, Tokyo, Japan). Each iso-
late was tested for susceptibility to ampicillin, 
chloramphenicol,  trimethoprim-sulphamethoxa-
zole, tetracycline, nalidixic acid, ciprofloxacin, 
mecillinam, ceftriaxone, and gentamicin by the 
Kirby-Bauer disc-diffusion method in 1991-1992 
(11,18). Antimicrobial susceptibility was deter-
mined by the Clinical Laboratory Standards In-
stitute (CLSI; formerly NCCLS) guidelines using 
Muller-Hinton agar, commercial antimicrobial 
discs (Oxoid, Basingstoke, United Kingdom), 
and Escherichia coli (ATCC 25922) as reference 
strain (18). During 2001-2002, isolates were test-
ed to an additional eight antimicrobial agents: 
erythromycin, azithromycin, amoxicillin-clavu-
lanate, cephalothin, streptomycin, rifampicin, 
moxifloxacin, and levofloxacin. MICs of nali-
dixic acid, ciprofloxacin, levofloxacin, ceftriax-
one, and azithromycin were determined by E-
test (AB Biodisk, Solna, Sweden) for a subset of 
Shigella isolates during 2001-2002.
Production of extended-spectrum ß-lactamase 
(ESBL) was detected by the double-disc synergy 
test (DDST) using cefotaxime (30 μg), ceftriaxone 
(30 μg), and ceftazidime (30 μg) discs placed 20 
mm (centre to centre) from the amoxicillin (20 
μg)/clavulanate (10 μg) disc, and an increase in 
diameter of zone of inhibition by the synergy of 
clavulanate indicated production of ESBL (19). 
Transfer of ceftriaxone resistance plasmid by 
conjugation
Conjugation between ceftriaxone-resistant Shigella 
isolates (donor) and Escherichia coli K12 strain 
(F-, lac-, NalR) was performed according to the 
method of Neu et al. (20). Transconjugants were 
selected on MacConkey agar containing ceftri-
axone (6 µg/mL) that produce lactose-ferment-
ing pink colonies in contrast to non-lactose-fer-
menting pale colonies of Shigella. All putative 
transconjugants were examined for antimicro-
bial susceptibility and plasmid profiles to obtain 
transconjugants. They were tested for production 
of ESBL (18). All transconjugants were cultured 
twice on MacConkey agar plate containing cef-
triaxone (6 µg/mL) to exclude contamination with 
donors. In the second transfer of R-plasmid by 
conjugation, ceftriaxone resistance and produc-
tion of ESBL were transferred from transconju-
gants E. coli to ceftriaxone-susceptible and tri-
methoprim-sulphamethoxazole-resistant wild 
Shigella sonnei. The second-generation Shigella 
transconjugants were selected on MHA plates 
supplemented with ceftriaxone (6 µg/mL) and Rahman M et al. Increasing antimicrobial resistance of Shigella
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trimethoprim (24 µg/mL) and were tested for 
antimicrobial susceptibility, ESBL, and R-plasmid. 
Plasmid analysis
Plasmid DNA was extracted from four ceftriax-
one-resistant Shigella isolates and all transcon-
jugants according to the method of Portnoy et al. 
(21) and was separated by electrophoresis in 
0.5% agarose gel, stained, and visualized. Ref-
erence plasmid markers—V517 and 39R861—
were used for determining the size of unknown 
plasmids. 
Statistical analysis
The significance of differences in the proportions 
of antimicrobial resistance and of the relative 
prevalence of each Shigella species was determined 
by the chi-square test. Two-tailed tests were ap-
plied.
RESULTS 
Of 266 of Shigella isolates tested for antimicrobial 
susceptibilities by the disc-diffusion method in 
2001-2002, S. flexneri (51%) was the predominant 
species, followed by S. boydii, S. sonnei, and S. 
dysenteriae (Table 1). Overall, Shigella isolates 
had high rates of resistance to tetracycline (79%), 
trimethoprim-sulphamethoxazole (72%), ampi-
cillin (56%), nalidixic acid (51%), and chloram-
phenicol (42%). Moderate-to-low rate of resis-
tance to azithromycin (16%), gentamicin (4%), 
mecillinam (3%), and third-generation cephalo-
sporins (TGC), such as cefixime (2%) and cef-
triaxone (2%) was observed. Many isolates were 
intermediate to azithromycin (62%), amoxicil-
lin-clavulanate (26%), ciprofloxacin (12%), and 
mecillinam (3%). No resistance to levofloxacin 
and moxifloxacin was detected. Resistance to 
azithromycin and third-generation cephalospo-
rins was detected for the first time among recent 
(2001-2002) isolates in our study. None of the 
Shigella isolates had complete resistance to cip-
rofloxacin. 
Overall, MDR strains defined as simultaneously re-
sistant to ≥3 of eight useful antimicrobial agents 
(ampicillin, trimethoprim-sulphamethoxazole, 
nalidixic acid, ciprofloxacin, mecillinam, tetra-
cycline, azithromycin, and ceftriaxone/cefixime) 
were detected in 63% of the isolates (Table 2). It 
was significantly high (94%, p<0.01) in S. dysen-
Table 1. Antimicrobial susceptibility results of Shigella isolates by the disc-diffusion method, 
2001-2002 (n=266)
Antimicrobial agent
Percentage of resistance (intermediate) among Shigella species 
S. boydii 
(n=52)
S. dysente-
riae (n=35)
S. flexneri 
(n=136)
S. sonnei 
(n=43)
Total 
(n=266)
Ampicillin 39 88 (7) 78 16 56 (2)
Amoxicillin/clavulanate 0 (17) (37) 0 (42) 5) 0 (26)
Trimethoprim- 
   sulphamethoxazole 42 (8) 90 68 (5) 87 72 (3)
Mecillinam 0 (0.5) 9 (3) 1 (1.5) 0  3 (3)
Nalidixic acid 33 (3) 98 18 (23) 54 51 (7)
Ciprofloxacin 0 (17) 0 (2) 0 (3) 0 (30) 0 (12)
Ceftriaxone/cefixime 3 0 0  5 2
Azithromycin 8 (78) 10 (73) 8 (38) 38 (60) 16 (62)
Tetracycline 58 90 85 (3) 78 79 (1)
Chloramphenicol 11 77 65 8 42
Erythromycin 100 98 (2) 93 (7) 100 97 (3)
Levofloxacin 0 0 0 0 0
Moxifloxacin 0 0 0 0 0
Rifampicin 100 100 100 100 100
Streptomycin 81 (19) 76 85 (15) 81 81 (8)
Cephalothin 19 0 (49) 0 41 14 (13)
Gentamicin 0 29 0 0 4
Figures in parentheses indicate percentages of strains exhibiting intermediate in resistance Rahman M et al. Increasing antimicrobial resistance of Shigella
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teriae, followed by S. sonnei (60%) and S. flexneri 
(58%) and was low in S. boydii (27%, p<0.01). 
Resistance to ampicillin, trimethoprim-sulpha-
methoxazole, nalidixic acid, and tetracycline 
was most frequent (48%), followed by resistance 
to ampicillin, trimethoprim-sulphamethoxazole, 
and tetracycline (R-type ApSXTTe) (18%), nalidixic 
acid, trimethoprim-sulphamethoxazole, and 
tetracycline (R-type NalSXTTe) (14%). Resistance 
to one and two drug(s) was 8% and 19% respec-
tively. Only 26 (10%) isolates were susceptible 
to all eight drugs tested.
We compared resistance frequencies of Shigella 
isolates of 2001-2002 with those isolated during 
1991-1992 (Table 3), which constituted part of 
our previous report (11). Resistance increased 
during the 2000s. Of note, the resistance to tri-
methoprim-sulphamethoxazole increased from 
52% to 72% (p<0.01), resistance to nalidixic acid 
from 19% to 51% (p<0.01), and mecillinam from 
0.5% to 3% (p<0.01). Resistance to ampicillin, 
tetracycline, and chloramphenicol was high 
(range 49-79%) in 1991-1992 and remained al-
most unchanged in 2001-2002 (Table 2). Strains 
Table 2. Patterns of resistance* of Shigella isolates to antimicrobial agents (n=266) in 2001-2002
Resistance to number of drugs, number of 
strains (%)
Resistance phenotype
   Type  No. of strains
Resistance to ≥3 drugs, MDR strains, 167 (63)
Resistance to 6 drugs, 3 AAzCrNSXTT   2
ACrMNSXTT   1
Resistance to 5 drugs, 6 AAzCrNSXT   1
AMNSXTT   3
AAzNSXTT   2
Resistance to 4 drugs, 86 ANSXTT 80
AzNSXTT   6
Resistance to 3 drugs, 72 ANT   5
AzNT   2
ASXTT 33
AAcT   2
AzSXTT   5
NSXTT 24
Resistance to two drugs, 51 (19)
AT 11
AzN   5
AzT   2
ASXT   2
NT   2
SXTT 29
Resistance to one drug, 22 (8)
Az  2
N  6
SXT  7
T  7
Susceptible, 26 (10) - 26
*Strains exhibiting intermediate resistance were not included
A=Ampicillin; Az=Azithromycin; C=Ciprofloxacin; Cr=Ceftriaxone; M=Mecillinam; MDR=Multi-
drug-resistant phenotype; N=Nalidixic acid; SXT=Trimethoprim-sulphamethoxazole; 
T=TetracyclineRahman M et al. Increasing antimicrobial resistance of Shigella
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Table 3. Comparison of antimicrobial resistance* of Shigella isolates to 12 antimicrobial agents by 
the disc-diffusion method between 1991-1992 and 2001-2002
                                                                                     Resistance rate (%) of Shigella isolates
Antimicrobial agent 1991-1992
(n=369)
2001-2002
(n=266)
p value
Trimethoprim-sulphamethoxazole 52 72 <0.01
Nalidixic acid 19 51 <0.001
Mecillinam 0.5 3 <0.001
Ampicillin 53 56 NS
Azithromycin NT 16 ND
Tetracycline 74 79 NS
Ceftriaxone 0 2 ND
Cefixime NT 2 ND
Amoxicillin-clavulanate NT 0 ND
Chloramphenicol 49 42 NS 
Gentamicin 0.2 4 <0.01
Ciprofloxacin 0 0 NS
*Strains exhibiting intermediate resistance were not included
ND=Not done; NS=Not significant; NT=Not tested
with MDR phenotype increased to 63% in 2001-
2002 from 52% (p<0.007) in 1991-1992.   
The MIC results of 154 available isolates (2001-
2002) to nalidixic acid, ciprofloxacin, levofloxa-
cin, azithromycin, and ceftriaxone are shown in 
the Figure. High modal MICs and MIC90 of na-
lidixic acid (modal MIC 128 µg/mL and MIC90 
256 µg/mL) and azithromycin (modal MIC of 6 
µg/mL and MIC90 8 µg/mL) and very low modal 
MIC (0.047 µg/mL) and MIC90 (0.023 µg/mL) of 
ceftriaxone were observed. 
Of four Shigella isolates that were resistant to 
third-generation cephalosporins (TGC), two iso-
lates of S. sonnei were highly resistant to ceftri-
axone (MIC >256 µg/mL), and S. flexneri and S. 
boydii were intermediate to it (MIC 24 µg/mL).   
However, all but one ceftriaxone-resistant strain 
was susceptible to mecillinam.
MIC of ciprofloxacin-differentiated isolates hav-
ing high MICs (0.064-0.38 µg/mL) and MIC90 
(0.25 µg/mL) exhibiting decreased susceptibility 
to ciprofloxacin and nalidixic acid resistance 
(MIC ≥32 µg/mL) from nalidixic acid-susceptible 
(MIC <32 µg/mL) and ciprofloxacin-susceptible 
isolates having 10-fold lower MIC90 (MIC 0.023 
µg/mL) and low MIC (range 0.012-0.047 µg/mL, 
Table 4). Levofloxacin showed similar results as 
ciprofloxacin. Of 154 Shigella isolates, decreased 
susceptibility to ciprofloxacin and resistance to 
nalidixic acid were detected among 110 (71%) 
strains. All isolates having decreased susceptibi-
lity to ciprofloxacin by MIC were susceptible to 
ciprofloxacin by the disc-diffusion method and 
resistant to nalidixic acid by the MIC and disc-
diffusion method. Of 105 MDR strains tested, 
91%  exhibited  decreased  susceptibility  to  cip-
rofloxacin  compared  to  29%  of  49  non-MDR 
strains (relative risk=3.20, p<0.00001). 
Three (two S. sonnei and one S. boydii) of four 
TGC-resistant strains were susceptible to amoxi-
cillin-clavulanate and positive in DDST, indicating 
production of a class A ESBL (19), as described 
earlier (22). We were able to transfer ß-lactam 
resistance and ESBL production of these TGC-
resistant strains to E. coli and Shigella by con-
jugation, which was encoded by a 50-MDa au-
totrasferable R-plasmid. The fourth isolate (S. 
flexneri) was resistant to amoxicillin-clavulanate 
but negative in DDST, thus exhibiting a class C 
(Amp C) ß-lactamase phenotype (19) mediated 
by a 94-MDa autotrasferable R-plasmid (22). 
DISCUSSION
Shigella causes invasive infection of the intestine 
that presents the most pressing challenge for 
providing effective antimicrobial therapy. Due 
to the emergence of resistance, antimicrobial 
agents, such as sulphonamides, tetracycline, 
ampicillin, trimethoprim-sulphamethoxazole, 
nalidixic acid, and mecillinam have all in suc-Rahman M et al. Increasing antimicrobial resistance of Shigella
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Table 4. Correlation of results of the disc-diffusion method with that of ciprofloxacin MICs in 
Shigella isolates (n=154)
No. of 
strains
 Disc-diffusion results  Range of MIC (*MIC90) µg/mL 
     Nalidixic acid             Ciprofloxacin                                                         
Nalidixic acid 
(30 µg)
Ciprofloxacin
(1 µg)
44 Susceptible  Susceptible  1-<32 (8) 0.012-0.047 (0.023)
110          Resistant Susceptible  32->256 (256) 0.064-0.38 (0.25)
*MIC90 was calculated separately for 44 nalidixic acid-susceptible and 110 nalidixic acid-resistant 
strains; MIC=Minimum inhibitory concentration
cession been used as first-line drugs in Bangla-
desh and many countries of the world (2,7,12-
14,23). During the past several decades, the 
organisms have progressively become resistant 
to most useful and inexpensive antimicrobial 
agents (7,8,11). Our study demonstrates an in-
creasing incidence and spectrum of antimicrobial 
resistance of Shigella isolates in Bangladesh in 
2001-2002. Rates of resistance to ampicillin, tri-
methoprim-sulphamethoxazole, and nalidixic 
acid increased to more than 50%. The resistance 
to tetracycline and chloramphenicol, which 
are not used currently for treating shigellosis, 
remained high and unchanged during the last 
decade. It is likely that the resistance rates ob-
served in our hospital-based microbiology labo-
ratory reflect the prevalence of resistance that 
exists in the community since nearly all cases 
of shigellosis were community-acquired, and 
the cultures were obtained on the day of admis-
sion. By analyzing the trends in the resistance 
patterns of various Shigella spp., we found that 
S. dysenteriae was at present significantly more 
resistant, followed by S. flexneri and other Shigella 
spp., in Bangladesh, especially to commonly-used 
antimicrobial agents. This finding is of special 
importance because S. flexneri is at present the 
predominant species in Bangladesh, like many 
other developing countries.   
Fig. Modal minimum inhibitory concentrations of some useful antimicrobial agents among
       Shigella isolates (n=154) in 2001-2002, showing no signiﬁcant increase of MIC to ceftriaxone
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At present, pivmecillinam (oral form of mecil-
linam), fluoroquinolones, azithromycin, and 
third-generation cephalosporins (cefixime) are 
used in many countries for treating shigellosis 
caused by Shigella resistant to all first-line drugs. 
Pivmecillinam is currently used as an empirical 
antimicrobial therapy for shigellosis in Bangla-
desh with caution since resistance to it is emerg-
ing. The rate of mecillinam resistance, observed 
in the present study, is significantly lower than 
that observed in our earlier study in Bangladesh 
(11). This was due to lack of precise guidelines 
for determining susceptibility to mecillinam in 
the past that inherently overestimated the re-
sistance rate. We used the CLSI (formerly NC-
CLS) methodology (24) for the determination of 
mecillinam susceptibility that reflects the true 
resistance rate in the present study. Azithromy-
cin was found to be effective in treating shig-
ellosis both in children and adults, including 
multidrug-resistant Shigella-associated infections 
(6,13). High modal MICs (6 µg/mL) and MIC90 
(8 µg/mL) of azithromycin for Shigella isolates 
were observed in our study, and we detected 
in-vitro resistance to azithromycin in Shigella 
for the first time in Bangladesh. It is not clear 
why Shigella exhibits high modal MIC values 
to azithromycin. It is surprising that a signifi-
cant proportion of isolates are resistant to this 
drug, although the drug is not commonly used 
for treating shigellosis in Bangladesh. However, 
the frequent use of macrolides for other infec-
tions and high carriage rate of Shigella in the gut 
of apparently healthy humans in Bangladesh 
might contribute to the emergence and spread 
of azithromycin-resistant Shigella strains (25). 
The significance of in-vitro resistance of Shigella 
to azithromycin is still unknown since intracel-
lular concentration of azithromycin achieved 
in colonic cells and leucocytes exceeds serum 
concentration by 100-fold or more that could 
be fatal for intracellular bacteria (26). It should 
be mentioned that the two zones of inhibition 
produced by azithromycin by the disc-diffusion 
method and E-test sometimes caused difficulty 
in interpretation of results.
Quinolones are a good choice for the treatment 
of shigellosis in adults (3,13). Nalidixic acid was 
effective (23) and approved for use in the treat-
ment of shigellosis in children aged less than 
three months. However, >50% of our Shigella 
isolates were resistant to nalidixic acid like many 
other developing countries (2,3,6,8). Fluoroqui-
nolones (ciprofloxacin and norfloxacin) are also 
effective in treating nalidixic acid-resistant shig-
ellosis, but paediatric use is limited by concerns 
about arthopathy and chondrotoxicity. Howev-
er, reported data suggest that they are generally 
safe for the treatment of shigellosis in children 
(3,27). In 1994, S. dysenteriae type 1, resistant to 
nalidixic acid having decreased susceptibility to 
ciprofloxacin (MIC >0.125 µg/mL), was reported 
for the first time in Bangladesh by our group (9). 
The isolation rate of such strains of Shigella re-
markably increased to 71% in 2001-2002 involv-
ing all species. The importance of strains having 
decreased susceptibility to fluoroquinolones was 
revealed recently by an outbreak of S. dysente-
riae type 1 in 2002 in eastern India that affected 
1,728 persons (attack rate of 25.6%), resulting 
in 16 deaths (28). Suboptimal clinical responses, 
therapeutic and microbiologic (positive culture 
after therapy) failures were associated with de-
creased ciprofloxacin susceptibilities of clinical 
isolates of Salmonella spp. and other bacteria in 
many countries, including India, the UK, Denmark, 
and the USA (29-31). To reduce such risks for 
humans, a recommendation has recently been 
made to lower breakpoint to 0.125 µg/mL for 
fluoroquinolones for Salmonella (29). With the 
increasing prevalence of Shigella strains having 
decreased susceptibility to fluoroquinolones 
such as ciprofloxacin, there is a need for care-
ful observation of the outcome of ciprofloxacin 
therapy for shigellosis to detect suboptimal 
clinical response or therapeutic failures, if any. 
However, the problem is that the strains hav-
ing decreased susceptibility to ciprofloxacin are 
not reported as these appear susceptible when 
subjected to ciprofloxacin-susceptibility testing 
(disc-diffusion method or by current MIC break-
points) by the CLSI guidelines. As suggested by 
our study, resistance to nalidixic acid appears 
to be a useful screening marker for decreased 
ciprofloxacin susceptibility. Hence, future stud-
ies should evaluate the clinical outcome of the 
treatment of shigellosis caused by strains hav-
ing susceptibility to ciprofloxacin but resistance 
to nalidixic acid. Further, in our earlier study, 
we detected a single-point mutation at codon 
Ser83 (TGC) to Tyr83 (TTC) in the quinolone 
resistance-determining region of gyrA gene of S. 
dysenteriae type 1, resulting in resistance to nali-
dixic acid with decreased susceptibility to cipro-
floxacin (9). Additional mutations in the same 
gene (codon 87) and/or parC (codons 80 and 
84) are known to result in complete resistance 
to ciprofloxacin (15). Thus, the use of fluoroqui-Rahman M et al. Increasing antimicrobial resistance of Shigella
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nolones is likely to result in complete resistance 
in Shigella strains harbouring resistance to nali-
dixic acid by additional mutations that we have 
witnessed recently in Bangladesh and India (32-
33). Interesting is the fact that the recent iso-
lates of ciprofloxacin-resistant S. dysenteriae type 
1 in Bangladesh and India appeared to originate 
by such mechanisms: a mutation in codon 87 of 
the gyrA and additional mutation in codon 80 
of parC genes  (32-33). Although R-plasmid-me-
diated quinolone resistance may occur on rare 
occasion (34), it is not unlikely that we will see 
more and more ciprofloxacin-resistant Shigella-
associated infections in the near future.
Cefixime and ceftriaxone were active against 
98% of our isolates in vitro, but there is some 
dispute regarding the clinical efficacy of cefix-
ime  in  treating  shigellosis  (6,35).  Recently, 
cefixime was found to be clinically effective in 
78% of children with shigellosis, predominantly 
caused by S. flexneri (6). However, it is an re-as-
suring finding that no increase in the MIC of 
ceftriaxone was observed in susceptible Shigella 
strains, unlike for ciprofloxacin or azithromycin. 
On the contrary, ESBL-mediated TGC resistance 
in Shigella strains was detected for the first time 
in Bangladesh. Detection of R-plasmid-medi-
ated ESBL in Shigella isolates, transferable to E. 
coli K 12 and Shigella by conjugation, suggests 
that ESBL could spread resistance to third-gen-
eration cephalosporins among Shigella spp. and 
other pathogens in the community (22,36-37). 
The limitation of our study is that we could not 
test all strains for antimicrobial susceptibility to 
detect exact rates of resistance to conventional 
and new useful antimicrobial agents. The isolates 
were from patients who came to the hospital for 
treatment or submitted faecal samples on the 
advice of physicians. Thus, strains might be asso-
ciated with severe form of illnesses or from cases 
not responding to therapy reflecting high rates 
of resistance compared to those existing in the 
community. However, high rates of resistance 
among Shigella isolates have been reported in 
the community of Bangladesh (7,11-12).      
Our study showed that Shigella strains developed 
resistance to many useful antimicrobial agents, 
including mecillinam, azithromycin, ceftriax-
one, and cefixime in Bangladesh. Options for 
antimicrobial therapy for such MDR Shigella-
associated infections are very limited leaving 
fluo-roquinoloes as the only option. Detection of 
decreased susceptibility to fluoroquinoloes in a 
high proportion of Shigella strains and complete 
fluoroquinolones-resistant S. dysenteriae type 1   
(15-16,28,31-32) clearly demands careful and 
judicial use of these drugs to avoid rapid emer-
gence and spread of resistance. 
In conclusion, physicians should be aware of the 
high rates of antimicrobial resistance and in-
creasing spectrum of resistance of Shigella spp. 
in Bangladesh. Continuous monitoring of the 
resistance patterns is essential, and antimicro-
bial susceptibility testing should be carried out 
on clinical isolates, and empirical antimicrobial 
therapy need to change accordingly. In addi-
tion, reduced susceptibility of Shigella strains to 
useful drugs should be identified by determi-
nation of MICs of antimicrobial agents for the 
early detection of the emergence of resistance. 
When indicated, pivmecillinam or ciprofoxacin 
might be considered for treating shigellosis with 
caution in Bangladesh.
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